RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties
RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
RespireRx Pharmaceuticals Inc. Announces Positive Results from Phase 2B PACE Study Conducted by the University of Illinois Dronabinol Reduces Symptoms of Obstructive Sleep Apnea
RespireRx Pharmaceuticals Inc. Announces Data for CX1739 Clinical Study in Opioid Induced Respiratory Depression
American Uranium's Lo Herma Resource Reaches 9.96Mlbs as Indicated Resources Grow 72% Prior to Publication of Planned Scoping Study
Angkor Resources' Subsidiary Meets with Cambodian National Refinery Systems to Discuss Potential In-Country Offtake for Block VIII Production
Nuvau Minerals Strengthens Its Board and Technical Team with the Appointment of David Palmer as a Director and Michael Sutton as Technical Advisor to the Board
